From its founding in 1992, Dendreon’s fortunes have risen and fallen with the sales of its flagship product, its sole marketed drug Provenge ® (sipuleucel-T), an autologous cellular immunotherapy for ...

It’s been more than a decade since Dendreon’s prostate cancer immunotherapy, Provenge, won FDA approval. Now, after a lackluster launch, a bankruptcy and multiple ownership changes, the biopharma is ...

BioVest’s immunotherapy BiovaxID®, if approved for follicular lymphoma, will likely gain acceptance on the market more quickly than the Dendreon’s prostate cancer vaccine Provenge, which was the first ...

CHICAGO, IL–Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological ...

Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses. That connection is ...

The Phase 3 IMPACT trial included a crossover design that allowed patients who were randomized to the control arm and experienced disease progression the opportunity to participate in an open label ...

PHILADELPHIA/NEW YORK, July 23 (Reuters) - Dendreon Corp hired JPMorgan Chase & Co as an adviser to help it find an international licensing partner for its prostate cancer vaccine Provenge, a source ...

We have seen that when PROVENGE is recommended to pick its five physicians, some patients may hesitate because they do not understand immunotherapy. We also know that when a well-educated consumer ...

Add Yahoo as a preferred source to see more of our stories on Google. Sep. 23—MORGANTOWN — Mon Health System has begun offering a specialized prostate cancer immunotherapy treatment not available ...